Deep search
Search
Images
Videos
Maps
News
Shopping
Copilot
More
Flights
Travel
Hotels
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Ozempic, Wegovy face US Medicare price negotiations
Medicare to negotiate price of Ozempic, Wegovy weight-loss drugs
Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.
Novo Nordisk’s Wegovy Achieves Weight-Loss of 20.7% at Higher Dose, Study Says
Novo Nordisk said patients taking a bigger dose of its blockbuster obesity drug lost more weight than those on a lower dose, without experiencing an increase in side-effects.
Ozempic, Wegovy and other new drugs are selected for Medicare’s price negotiations
Biden administration says popular weight loss drugs have been added to Medicare’s list of medications that will be negotiated directly between the government and drug manufacturers
20h
E-sellers of compounded weight-loss drugs fail to reveal risks, research shows
Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...
1d
Ozempic, Wegovy among drugs selected for Medicare's price negotiations
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
5d
on MSN
Zealand Seeks to Usurp Wegovy, Zepbound With New Obesity Drug
There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, ...
5d
'I feel blessed to get weight-loss jab' - but can the NHS afford it for all?
We meet some of the first NHS patients, as expert says funding everyone eligible would "bankrupt" the service.
2d
Gov. Hochul wants to lower cost of anti-obesity drugs, expand access to Medicaid recipients
The governor also said she would work with other states to leverage their combined purchasing power to reduce the cost of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback